For the quarter ending 2026-03-31, TRDA had -$14,608K decrease in cash & cash equivalents over the period. -$41,739K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -39,717 | -39,164 | -44,134 | -60,452 |
| Depreciation expense | 805 | 886 | 1,230 | 1,980 |
| Stockbased compensation expense | 4,744 | 4,358 | 5,116 | 10,135 |
| Amortization/(accretion) of marketable securities | 548 | 633 | 739 | 2,299 |
| Collaboration receivable | -390 | -19 | 16 | -2,500 |
| Prepaid expenses and other current assets | 2,461 | -1,504 | -3,731 | -2,407 |
| Right-of-use assets, operating leases | -1,693 | -1,671 | -3,559 | -5,439 |
| Other non-current assets | 20 | -93 | -36 | -85 |
| Accounts payable | 641 | -877 | 1,309 | -2,231 |
| Accrued expenses and other current liabilities | -5,952 | 2,150 | 3,737 | -1,145 |
| Income tax payable | 0 | -620 | 620 | -667 |
| Operating lease liabilities | -1,182 | -1,468 | -2,343 | -4,464 |
| Deferred revenue | -88 | -122 | -419 | -19,284 |
| Net cash used in operating activities | -41,695 | -32,203 | -28,313 | -67,996 |
| Purchases of property and equipment | 44 | -207 | -171 | 1,419 |
| Purchases of marketable securities | 11,825 | 18,473 | 26,566 | 96,574 |
| Maturities of marketable securities | 38,856 | 47,385 | 75,504 | 136,573 |
| Net cash provided by investing activities | 26,987 | 29,119 | 49,109 | 38,580 |
| Proceeds from issuance of common stock under the employee stock purchase plan | - | 145 | 0 | 317 |
| Proceeds from issuance of common stock and pre-funded warrants in registered direct offering, net of issuance costs paid | - | - | 0 | 0 |
| Proceeds from issuance of common stock and pre-funded warrants in registered direct offering, net of issuance costs paid-Registered Direct Offering | - | 0 | - | - |
| Proceeds from exercise of stock options | 100 | 47 | 8 | 370 |
| Net cash provided by financing activities | 100 | 192 | 8 | 687 |
| Net decrease in cash, cash equivalents and restricted cash | -14,608 | -2,892 | 20,804 | -28,729 |
| Cash, cash equivalents, and restricted cash at beginning of period | 94,344 | 97,236 | 105,161 | - |
| Cash, cash equivalents, and restricted cash at end of period | 79,736 | 94,344 | 97,236 | - |
Entrada Therapeutics, Inc. (TRDA)
Entrada Therapeutics, Inc. (TRDA)